Physician

Oncology

Dr. Barbara A. Conley, MD

Barbara Conley practices Oncology. Barbara Conley is also a published physician. She has 80 paper published. The most recent paper is: Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.

Publications

Endoglin is required in Pax3-derived cells for embryonic blood vessel formation.
Application of molecular profiling in clinical trials for advanced metastatic cancers.
Biomarkers: Exceptional responders-discovering predictive biomarkers.
CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer.
AHNAK2 Participates in the Stress-Induced Nonclassical FGF1 Secretion Pathway.
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Criteria for the use of omics-based predictors in clinical trials.
Rare Case of Hairy Cell Leukemia With Brain Parenchymal Involvement: A Diagnostic Dilemma.
BMP9 regulates endoglin-dependent chemokine responses in endothelial cells.
An unusual case of autoimmune pancreatitis presenting as pancreatic mass and obstructive jaundice: a case report and review of the literature.
Endoglin regulates cancer-stromal cell interactions in prostate tumors.
Unusual presentation of large-cell poorly differentiated neuroendocrine carcinoma of the epiglottis.
Endoglin plays distinct roles in vascular smooth muscle cell recruitment and regulation of arteriovenous identity during angiogenesis.
Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects.
Novel biochemical pathways of endoglin in vascular cell physiology.
Endoglin is required for myogenic differentiation potential of neural crest stem cells.
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors.
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Treatment of advanced head and neck cancer: what lessons have we learned?
Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and...
Clinical trial designs for predictive marker validation in cancer treatment trials.
Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration.
Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain.
Detection of prostate cancer and predicting progression: current and future diagnostic markers.
Clinical trials referral resource. Targeted therapy in squamous cell cancers of the head and neck.
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.
Transient pancytopenia as an initial manifestation of hereditary spherocytosis. A case report.
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.
Workshop report: organ preservation strategies in advanced head and neck cancer--current status and future directions.
Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.
Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base.
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.
A phase-I study of cpt-11, weekly bolus 5-fu and leucovorin in patients with metastatic cancer.
A pilot trial of paclitaxel, carboplatin, and concurrent radiotherapy for unresectable squamous cell carcinoma of the head and neck.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Combined modalities in the treatment of head and neck cancers.
Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for r...
Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing in...
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck.
Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques.
Clinical trials, referral resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
Clinical trials. NCI clinical trials in colon cancer.
Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice.
Clinical trials referral resource. Clinical trials in gastric cancer.
National Cancer Institute Clinical Trials Program in Colorectal Cancer.
Clinical trials referral resource. Clinical trials of multimodality approaches for advanced esophageal cancer.
Effects of fenretinide (4-HPR) on dark adaptation.
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clinical trials referral resource. Clinical trials in head and neck cancer.
Current status of retinoids in chemoprevention of oral squamous cell carcinoma: an overview.
Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics.
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a.
Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.
Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by re...
N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma.
Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics.
Reduction of dithizone-reactive granules of blood granulocytes in humans and rats bearing tumor.
Salivary concentrations of hexamethylene bisacetamide (HMBA) in patients receiving 5-day continuous infusions.
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
Pharmacodynamics in cancer therapy.
Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function.
The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Approaches to optimal dosing of hexamethylene bisacetamide.
NIH symposium summary: organ preservation therapies for squamous cancers of the head and neck.
Prognostic and predictive markers in cancer.
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Histone deacetylation : an attractive target for cancer therapy?
Salivary gland cancers: current treatments, molecular characteristics and new therapies.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced mal...
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Schools

Michigan State University College Of Human Medicine
Greater Baltimore Med Center
University MD Cancer Center

Doctors Specialties

Medical Oncology
Oncology

Accepted Insurances

Education

University of Maryland
Michigan State University College of Human Medicine

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Cheryl D. Kovalski, DO This Doctor is OpenDoctor Recommended.
	Dr. Elena C. Coppola, DO This Doctor is OpenDoctor Recommended.
	Dr. Shalini Thoutreddy, MD This Doctor is OpenDoctor Recommended.
	Dr. Nikolay V. Dimitrov, MD This Doctor is OpenDoctor Recommended.